Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial

Fig. 2

A Kaplan-Meier estimates of progression-free survival in patients (n = 231) treated with carboplatin/paclitaxel plus bevacizumab (experimental group). Patients are separated into two groups: those with the VEGFR-2 rs2305945 G/G variant (n = 93) and those with the VEGFR-2 rs2305945 G/T or T/T variant (n = 138). The median PFS was 18.2 months for those patients with the VEGFR-2 rs2305945 G/G variant and 23.0 months for those with the VEGFR-2 rs2305945 G/T or T/T variant (HR 0.74, P = 0.07). B Kaplan-Meier estimates of progression-free survival in patients (n = 214) treated with carboplatin/paclitaxel (control group). Patients are separated into two groups: those with the VEGFR-2 rs2305945 G/G variant (n = 83) and those with the VEGFR-2 rs2305945 G/T or T/T variant (n = 131). The median PFS was 21.2 months for those patients with the VEGFR-2 rs2305945 G/G variant and 15.6 months for those with the VEGFR-2 rs2305945 G/T or T/T variant (HR 1.14, P = 0.48)

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us